LBA71 A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE Trial Interim Analysis)
ANNALS OF ONCOLOGY（2023）
关键词
EGFR Mutations
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要